187 related articles for article (PubMed ID: 36245005)
1. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G; Canfora M; Terrenato I; Agnoletto C; Agustoni F; Amoroso L; Baldassarre G; Curigliano G; Delmonte A; De Luca A; Fiorentino M; Gregorc V; Ibrahim T; Lazzari C; Mastronuzzi A; Pronzato P; Santoro A; Scambia G; Tommasi S; Vingiani A; Giacomini P; De Maria R
J Exp Clin Cancer Res; 2022 Oct; 41(1):305. PubMed ID: 36245005
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
[TBL] [Abstract][Full Text] [Related]
3. Clinician Perspectives Regarding the Impact of Information Technology on Multidisciplinary Tumor Boards: A National Comprehensive Cancer Network Survey.
Arafat W; Fu P; Wagner AJ; Osterman T; Martin DB; Sugalski J; Heinrichs T; Racz J; Tevaarwerk AJ
JCO Clin Cancer Inform; 2023 Sep; 7():e2300056. PubMed ID: 37944060
[TBL] [Abstract][Full Text] [Related]
4. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
[TBL] [Abstract][Full Text] [Related]
5. Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.
Jain NM; Schmalz L; Cann C; Holland A; Osterman T; Lang K; Wiesner GL; Pal T; Lovly C; Stricker T; Micheel C; Balko JM; Johnson DB; Park BH; Iams W
Oncologist; 2021 Nov; 26(11):e1962-e1970. PubMed ID: 34390291
[TBL] [Abstract][Full Text] [Related]
6. Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy.
Irelli A; Chiatamone Ranieri S; Di Giacomo D; Malatesta S; Patruno LV; Tessitore A; Alesse E; Cannita K
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980613
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.
Engelhardt M; Ihorst G; Schumacher M; Rassner M; Gengenbach L; Möller M; Shoumariyeh K; Neubauer J; Farthmann J; Herget G; Wäsch R
BMC Cancer; 2021 Feb; 21(1):173. PubMed ID: 33596881
[TBL] [Abstract][Full Text] [Related]
8. Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.
Sotelo-Rodríguez C; Vallejo-Ardila D; Ruiz-Patiño A; Chamorro DF; Rodríguez J; Moreno-Pérez DA; Carranza H; Otero J; Vargas C; Archila P; Rojas L; Zuluaga J; Rubio C; Ordóñez-Reyes C; Garcia-Robledo JE; Mejía S; Jaller E; Arrieta O; Cardona AF
JCO Glob Oncol; 2024 Jan; 10():e2300011. PubMed ID: 38237094
[TBL] [Abstract][Full Text] [Related]
9. Molecular Tumor Boards: current practice and future needs.
van der Velden DL; van Herpen CML; van Laarhoven HWM; Smit EF; Groen HJM; Willems SM; Nederlof PM; Langenberg MHG; Cuppen E; Sleijfer S; Steeghs N; Voest EE
Ann Oncol; 2017 Dec; 28(12):3070-3075. PubMed ID: 29045504
[TBL] [Abstract][Full Text] [Related]
10. Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network.
Marchetti A; Barbareschi M; Barberis M; Buglioni S; Buttitta F; Fassan M; Fontanini G; Marchiò C; Papotti M; Pruneri G; Scarpa A; Stanta G; Tallini G; Troncone G; Veronese SM; Truini M; Sapino A
Pathologica; 2021 Aug; 113(4):262-271. PubMed ID: 34463674
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards.
Love TM; Anaya DA; Prime MS; Ardolino L; Ekinci O
PLoS One; 2022; 17(5):e0268477. PubMed ID: 35560035
[TBL] [Abstract][Full Text] [Related]
12. Practice and Impact of Multidisciplinary Tumor Boards on Patient Management: A Prospective Study.
Charara RN; Kreidieh FY; Farhat RA; Al-Feghali KA; Khoury KE; Haydar A; Nassar L; Berjawi G; Shamseddine A; El Saghir NS
J Glob Oncol; 2017 Jun; 3(3):242-249. PubMed ID: 28717766
[TBL] [Abstract][Full Text] [Related]
13. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
[TBL] [Abstract][Full Text] [Related]
14. Molecular tumour boards - current and future considerations for precision oncology.
Tsimberidou AM; Kahle M; Vo HH; Baysal MA; Johnson A; Meric-Bernstam F
Nat Rev Clin Oncol; 2023 Dec; 20(12):843-863. PubMed ID: 37845306
[TBL] [Abstract][Full Text] [Related]
15. Implementing multidisciplinary tumor boards in oncology: a narrative review.
Mano MS; Çitaku FT; Barach P
Future Oncol; 2022 Jan; 18(3):375-384. PubMed ID: 34787482
[TBL] [Abstract][Full Text] [Related]
16. Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine.
Ballatore Z; Bozzi F; Cardea S; Savino FD; Migliore A; Tarantino V; Chiodi N; Ambrosini E; Bianchi F; Goteri G; Filosa A; Barbisan F; Bartoli E; Papa R; Berardi R
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892804
[No Abstract] [Full Text] [Related]
17. Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
Mathew A; Davis S; Boby JM; R I A; Suryavanshi M; Dawood SS; Panda PK; Nag SM; Das A; Rohatgi N; Popat S; Shah RNH; Thampy C; Parikh AR; Yadav S; Mehta P; Singh R; Mukherji D; Shilpakar R; Mullapally SK; Sirohi B
JCO Glob Oncol; 2024 Mar; 10():e2300330. PubMed ID: 38484196
[TBL] [Abstract][Full Text] [Related]
18. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL
JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U
BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133
[TBL] [Abstract][Full Text] [Related]
20. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
Rolfo C; Manca P; Salgado R; Van Dam P; Dendooven A; Ferri Gandia J; Rutten A; Lybaert W; Vermeij J; Gevaert T; Weyn C; Lefebure A; Metsu S; Van Laere S; Peeters M; Pauwels P; Machado Coelho A
ESMO Open; 2018; 3(5):e000398. PubMed ID: 30094075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
